Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Celularity Inc

Get SEC filing alerts via email and in your feed for Celularity Inc

CELU CELUW

Celularity Inc

About Celularity Inc

Celularity Inc. specializes in regenerative and cellular medicines derived from placental tissue, developing off-the-shelf allogeneic cell therapies and advanced biomaterials. Its core offerings include placental-derived cell products, biomaterials for wound and tissue repair, and biobanking services. The company targets aging-related, degenerative, and immune disorders, leveraging proprietary manufacturing platforms and extensive IP to deliver scalable, accessible therapies and contract manufacturing solutions worldwide.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Celularity Inc

1
1
Celularity Inc Celularity Inc. Reports 51% Revenue Decline and Increased Net Loss for Fiscal Year 2025

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Celularity Inc Celularity Inc. Reports 43.2% Revenue Decline in Q3 2025, Faces Going Concern Issues

Via official filing (AI summary) | 7 months ago | 0 comments

3
1
Celularity Inc Celularity Inc. Reports 52.6% Revenue Decline and Increased Operational Losses in Q2 2025

Via official filing (AI summary) | 9 months ago | 0 comments

4
1
Celularity Inc Celularity Inc. Reports $19.8 Million Net Loss and 22.2% Revenue Decline in Q1 2025

Via official filing (AI summary) | 9 months ago | 0 comments

5
1
Celularity Inc Celularity Inc. Reports $57.9M Net Loss for 2024, Revenue Increases 138.1%

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Celularity Inc Celularity Inc. Reports 145.5% Revenue Growth but Faces Ongoing Financial Challenges

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Celularity Inc Celularity Inc. Reports 312% Revenue Growth, Net Loss Reduction in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments

8
1
Celularity Inc Celularity Inc. Reports 273% Revenue Growth, Improved Financials in Q1 2024

Via official filing (AI summary) | over 1 year ago | 0 comments